

## **Tasly Pharmaceuticals and Mauna Kea Technologies Announce Joint Venture and Licensing Agreements**

*Mauna Kea to form Joint Venture (JV) with Tasly to develop, manufacture and commercialize Cellvizio for the Chinese market.*

*JV also to acquire exclusive worldwide rights to develop and commercialize Cellvizio in the fields of Neurology and Neurosurgery*

*Subject to transferring IP assets and contributing licenses to the JV, Mauna Kea to receive 44% equity interest in the Joint Venture, cash payments totaling \$10 million, and Cellvizio purchasing commitments for 5 years*

*Agreement accelerates Mauna Kea's previously announced strategic repositioning*

***Webinar | July 12<sup>th</sup> 2022 at 6:00pm CEST (12:00pm EDT - New York)***

The Company's management will share more information about this strategic announcement

To register for the webinar:

<https://app.livestorm.co/p/c7bc528d-a7ca-41c2-9930-adb5ec378413>

A replay will be available on Mauna Kea Technologies' website  
(<https://www.maunakeatech.com/en/investors>)

**Shanghai, Paris and Boston, July 11, 2022 – 5:45 pm CEST – Mauna Kea Technologies (Euronext: MKEA, 'Mauna Kea') inventor of Cellvizio®**, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, and Tasly Pharmaceuticals (SH Exchange: 600535, 'Tasly') today announced the execution of an agreement to form a Joint Venture (JV).

Under terms of the agreement, Tasly and Mauna Kea will form a Joint Venture that will (i) commercialize selected Cellvizio indications in China, (ii) develop and commercialize Cellvizio globally in the fields of Neurology and Neurosurgery, and (iii) manufacture Cellvizio units for the Chinese market. The JV will utilize both existing distribution partners and its own network of China-based marketing professionals to accelerate market adoption.

In exchange for contributing licenses and other intellectual property to the JV, Mauna Kea will receive cash payments totaling \$10 million, a 44.1% equity interest in the JV, and a 5-year commitment to purchase minimum quantities of Cellvizio systems and probes. Mauna Kea's equity holdings are net of shares issued to Cenponte Tech Limited in consideration for strategic advisory services provided in

connection to the transaction. The Joint Venture will be majority owned and funded by Tasly and jointly managed by Tasly and Mauna Kea.

The Joint Venture will be in an immediate position to leverage Mauna Kea's position as global leader in probe and needle-based confocal laser endomicroscopy, with its FDA clearance for neurosurgery applications, its broad regulatory clearances in the Chinese market as well as its significant installed base in leading hospitals in China.

**Sacha Loiseau, Ph.D., founder and Chairman of Mauna Kea Technologies,** stated: "We are delighted to partner with Tasly Pharmaceuticals, a life sciences leader in Asia-Pacific with a global presence. This transaction both expands the addressable market for Cellvizio and increases Mauna Kea's capacity to invest further in product and clinical development, including molecular imaging and artificial intelligence. This announcement builds on the strategic repositioning we announced in December 2021 and our emphasis on forming capital-efficient partnerships that leverage the commercial reach of global biopharma and medtech firms while increasing patient access to Cellvizio."

**Kaijing Yan, Chairman of Tasly Pharmaceuticals Group, commented:** "The field of biomedical engineering is an important part of Tasly Pharmaceuticals' second growth curve strategy. The cooperation with Mauna Kea Technologies will enable us to quickly access large markets in China addressed by the multiple clinical applications of Confocal Laser Endomicroscopy. The recent advances in molecular imaging with Cellvizio are also of great interest to us since Tasly Pharmaceuticals could assist the Joint Venture in developing new combinations of Cellvizio with novel molecular markers, aligned with our vision of providing integrated solutions from diagnosis to treatment. We very much look forward to a fruitful and rich collaboration with Mauna Kea Technologies."

Cenponte Tech Limited and McDermott Will & Emery advised Mauna Kea Technologies on the transaction.

#### **About Tasly Pharmaceuticals Group**

Adhering to the business mission of "To share the joy of health with all", Tasly has always been promoting the integrative development of traditional Chinese medicine (TCM) and modern medicine. Tasly continuously focuses on the three disease fields of cardio-cerebro-vascular diseases, digestive and metabolic diseases and tumors, which have the largest market share and the fastest development in China. It is committed to providing drug R&D that is urgently needed for clinical use and even addresses the unmet needs in China's clinical market. By leveraging the coordinated development advantages of modern TCM, biological medicine and chemical medicine, it carries out the strategic layout of innovative drugs and continues to maintain its leading position in the industry and the development momentum of R&D and innovation. For more information, visit <http://www.tasly.com/>

#### **Tasly Pharmaceuticals**

+86 22 26736290

#### **About Mauna Kea Technologies**

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions.

The Cellvizio platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit [www.maunakeatech.com](http://www.maunakeatech.com).

**NewCap - Investor Relations**

Thomas Grojean  
+33 (0)1 44 71 94 94  
[maunakea@newcap.eu](mailto:maunakea@newcap.eu)

**Disclaimer****Mauna Kea Technologies**

This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. All statements other than statements of historical fact included in this press release, including, without limitation, those regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives of management for future operations are forward-looking statements. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties, including the risks set forth in Chapter 3 of the 2020 Universal Registration Document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on June 17, 2021 under number D-21-0566 and the amendment to the 2020 Universal Registration Document filed with the AMF on September 17, 2021, which are both available on the Company's website ([www.maunakeatech.com](http://www.maunakeatech.com)), and risks relating the economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. The distribution of this document may, in certain jurisdictions, be restricted by local regulations. Persons who come into possession of this document are required to observe all applicable local regulations relating to this document